Elixir Pharmaceuticals is making progress on the business side of healthy life extension research, as noted at LEF News. They're licensing a patent resulting from recent research into "MTP," an aging gene uncovered in a recent centenarian study. This isn't anything major or new on the research side of things, but it is important to see progress in the corporate organization of real anti-aging research. In the long run, corporate concerns are the source of most research funding in any given field. One successful company will mean many others will soon be funded to compete...we are seeing the start of that now.